
Iovance Biotherapeutics IOVA
$ 6.9
-5.61%
Iovance Biotherapeutics Total Assets | IOVA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 913 M | 910 M | 780 M | 664 M | 777 M | 768 M | 345 M | 481 M | 155 M | 172 M | 106 M | 46.5 M | 19.9 M | 29.4 K | 568 K | 1.46 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 913 M | 29.4 K | 384 M |
Quarterly Total Assets Iovance Biotherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 991 M | 916 M | 926 M | 913 M | 905 M | 907 M | 967 M | 910 M | 991 M | 964 M | 870 M | 780 M | 852 M | 757 M | 825 M | 664 M | 546 M | - | 701 M | 777 M | 829 M | 853 M | 751 M | 768 M | 768 M | 768 M | 768 M | 345 M | 345 M | 345 M | 462 M | 481 M | 271 M | 285 M | 307 M | 155 M | 174 M | 138 M | 155 M | 172 M | 182 M | 194 M | 101 M | 106 M | 112 M | 115 M | 114 M | 46.5 M | 17.4 M | 18.5 M | 18.1 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 29.4 K | 29.4 K | 29.4 K | 29.4 K | 568 K | 568 K | 568 K | 568 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 991 M | 29.4 K | 426 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cerus Corporation
CERS
|
222 M | $ 1.86 | -2.37 % | $ 355 M | ||
|
Beam Therapeutics
BEAM
|
1.48 B | $ 20.87 | -0.36 % | $ 2.06 B | ||
|
Inhibrx
INBX
|
308 M | $ 68.81 | -7.43 % | $ 3.24 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
404 M | $ 48.09 | -4.54 % | $ 5.52 B | ||
|
Revolution Medicines
RVMD
|
2.35 B | $ 161.01 | 0.99 % | $ 30.6 B | ||
|
Entera Bio Ltd.
ENTX
|
16 M | $ 3.29 | 0.15 % | $ 152 M | ||
|
Flexion Therapeutics, Inc.
FLXN
|
252 M | - | - | $ 459 M | ||
|
Legend Biotech Corporation
LEGN
|
1.73 B | $ 15.21 | -5.53 % | $ 5.61 B | ||
|
CytomX Therapeutics
CTMX
|
152 M | $ 2.04 | -0.73 % | $ 281 M | ||
|
China SXT Pharmaceuticals
SXTC
|
34.8 M | $ 2.67 | 2.9 % | $ 1.81 M | ||
|
Krystal Biotech
KRYS
|
1.33 B | $ 308.83 | -2.21 % | $ 8.94 B | ||
|
Kura Oncology
KURA
|
738 M | $ 6.91 | -6.05 % | $ 606 M | ||
|
Inhibikase Therapeutics
IKT
|
181 M | $ 1.31 | 0.38 % | $ 129 M | ||
|
Protara Therapeutics
TARA
|
209 M | $ 2.28 | -5.21 % | $ 97.7 M | ||
|
Heron Therapeutics
HRTX
|
256 M | $ 0.25 | -5.3 % | $ 41.7 M | ||
|
Inovio Pharmaceuticals
INO
|
74.3 M | $ 1.76 | 2.63 % | $ 82.5 M | ||
|
Corvus Pharmaceuticals
CRVS
|
71.1 M | $ 9.66 | -3.5 % | $ 763 M | ||
|
Aytu BioScience
AYTU
|
105 M | $ 2.66 | -0.37 % | $ 32.8 M | ||
|
Heat Biologics, Inc.
HTBX
|
124 M | - | -5.76 % | $ 99.8 M | ||
|
Innoviva
INVA
|
1.64 B | $ 18.42 | 0.03 % | $ 1.24 B | ||
|
BioCardia
BCDA
|
3.41 M | $ 0.77 | -0.08 % | $ 5.13 M | ||
|
Bio-Techne Corporation
TECH
|
2.59 B | $ 72.69 | -0.01 % | $ 11.3 B | ||
|
Kindred Biosciences, Inc.
KIN
|
95.8 M | - | 0.11 % | $ 419 M | ||
|
Alterity Therapeutics Limited
ATHE
|
46 M | $ 1.52 | -8.16 % | $ 9.72 B | ||
|
Shineco, Inc.
TYHT
|
79.1 M | - | -3.90 % | $ 97.2 M | ||
|
ORIC Pharmaceuticals
ORIC
|
409 M | $ 7.34 | -4.68 % | $ 644 M | ||
|
Certara
CERT
|
1.56 B | $ 10.56 | -1.12 % | $ 1.69 B | ||
|
Intec Pharma Ltd
NTEC
|
20.9 M | - | -12.45 % | $ 17.7 M | ||
|
Anika Therapeutics
ANIK
|
190 M | $ 13.26 | -0.15 % | $ 190 M | ||
|
Aprea Therapeutics
APRE
|
15.9 M | $ 0.23 | -52.81 % | $ 1.5 M | ||
|
Galectin Therapeutics
GALT
|
19.5 M | $ 2.68 | -4.63 % | $ 171 M | ||
|
Processa Pharmaceuticals
PCSA
|
7.81 M | $ 1.59 | -5.92 % | $ 2.08 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
837 M | $ 63.61 | -2.11 % | $ 6.61 B | ||
|
Progenity, Inc.
PROG
|
154 M | - | -3.47 % | $ 164 M | ||
|
Genprex
GNPX
|
10.2 M | $ 1.46 | -12.87 % | $ 1.36 M | ||
|
Strongbridge Biopharma plc
SBBP
|
121 M | - | 1.52 % | $ 136 M | ||
|
Nektar Therapeutics
NKTR
|
280 M | $ 30.23 | -7.1 % | $ 510 M | ||
|
Innate Pharma S.A.
IPHA
|
62.7 M | $ 0.87 | -7.57 % | $ 77.9 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
13 M | - | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
7.59 B | $ 60.42 | -1.64 % | $ 11.6 B | ||
|
Matinas BioPharma Holdings
MTNB
|
7.21 M | $ 0.75 | -9.23 % | $ 4.11 M | ||
|
Enanta Pharmaceuticals
ENTA
|
276 M | $ 7.6 | -4.82 % | $ 220 M | ||
|
Milestone Pharmaceuticals
MIST
|
114 M | $ 0.38 | -5.66 % | $ 40.4 M | ||
|
Lipocine
LPCN
|
17 M | $ 1.47 | -2.33 % | $ 8.01 M | ||
|
Seres Therapeutics
MCRB
|
138 M | $ 1.25 | -6.02 % | $ 11.1 M | ||
|
Oramed Pharmaceuticals
ORMP
|
231 M | $ 3.58 | -2.98 % | $ 148 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
1.26 B | $ 378.19 | -4.68 % | $ 8.48 B | ||
|
CEL-SCI Corporation
CVM
|
28.2 M | $ 1.2 | -18.37 % | $ 9.62 M | ||
|
Inventiva S.A.
IVA
|
119 M | $ 3.14 | -9.13 % | $ 188 M |